Authors	Title	Journal	Year	Volume	Pages
Lin JD, Liou MJ, Chao TC, Weng HF, Ho	Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node	Endocr Relat Cancer	1999	6(1)	109–15
Seabold JE, Gurll N, Schurrer ME, Aktay R, Kirchner	Comparison of 99mTc–methoxyisobutyl isonitrile and 201Tl scintigraphy for detection	J Nucl Med	1999	40(9)	1434–40
McDougall	Cancer deaths after 131I	Nucl Med	1999	20(5)	407–9
Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle	Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population–based cohort study.	Lancet	1999	353(917(	2111–5
Doi SA, Woodhouse	Ablation of the thyroid remnant and 131I dose in differentiated	Clin Endocrinol	2000	52(6)	765–73
Kebebew E, Clark	Medullary thyroid cancer.	Curr Treat Options	2000	1(4)	359–67
Yim JH, Doherty	Papillary thyroid cancer.	Curr Treat Options	2000	1(4)	329–38
Kebebew E, Clark	Differentiated thyroid cancer: "complete" rational approach.	World J Surg	2000	24(8)	942–51
Griffiths PA, Jones GP, Marshall C, Powley	Radiation protection consequences of the care of a terminally ill patient having	Br J Radiol	2000	73(875)	1209–12
Shingu K, Kobayashi S, Yokoyama S, Fujimori M, Asanuma K, Ito KI, Hama Y, Maruyama M, Kusama	The likely transformation of papillary thyroid carcinoma into anaplastic carcinoma during postoperative radioactive iodine–131 therapy: report of a	Surg Today	2000	30(10)	910–3
La Quaglia MP, Black T, Holcomb GW 3rd, Sklar C, Azizkhan RG, Haase GM, Newman	Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee	J Pediatr Surg	2000	35(6)	955–9; discussion 960
Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins	Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty–	Thyroid	2000	10(3)	261–8
Sautter–Bihl ML, Raub J, Hetzel–Sesterheim M, Heinze	Differentiated thyroid cancer: prognostic factors and influence of treatment on the	Strahlenther Onkol	2001	177(3)	125–31
Chas J, Kowalczyk A, Siekierzynski M, Dziuk E, Janiak	[Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant	Wiad Lek	2001	54 Suppl	312–20
Dequanter D, Abdoulaye D, Lothaire P, Gebhart	[Isolated pelvic metastasis of thyroid cancer].	Ann Endocrinol (Paris)	2001	62(6)	521–4
Hadjieva	Scoring patients' risk in	Onkologie	2001	24(6)	561–8
Tutal E, Tutuncu NB, Akcaer N, Bilezikci B, Guvener N, Arican	Unusual case of metastatic thyroid nodule: nonpalpable breast mass as origin.	Endocr Pract	2001	7(5)	379–82
Singer	Long–term comparative cancer mortality after use of radio–iodine in the treatment of	J Insur Med	2001	33(2)	138–42
Bal CS, Padhy AK, Kumar	Clinical features of differentiated thyroid carcinoma in children and adolescents	Nucl Med Commun	2001	22(8)	881–7

Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ,	Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-	Clin Endocrinol (Oxf)	2001	55(1)	47-60
Chew SL, Monson JP, Besser GM, Al-Balawi IA, Meir HM, Yousef MK, Nayel HA, Al-	Differentiated thyroid carcinoma referred for radioiodine therapy.	Saudi Med J	2001	22(6)	497-503
Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess	A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English	Cancer	2001	91(3)	505-24
Smit	[The initial treatment of patients with differentiated	Ned Tijdschr	2002	146(10)	454-7
Patel A, Jhiang S, Dogra S, Terrell R, Powers PA, Fenton C, Dinauer CA, Tuttle RM, Francis	Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.	Pediatr Res	2002	52(5)	737-44
Grigsby PW, Gal-or A, Michalski JM,	Childhood and adolescent thyroid carcinoma.	Cancer	2002	95(4)	724-9
Oueslati Z, Aloui M, Gritli S, Touati S, el-May A, Gamoudi A, Ben-Slimene F, Ladgham	[Thyroid papillary microcarcinoma. Salah Azaiz Institute experience].	Rev Laryngol Otol Rhinol (Bord)	2002	123(1)	39-42
Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman	Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer.	Arch Otolaryngol Head Neck	2002	128(7)	825-8
Lee YM, Lo CY, Lam KY, Wan KY, Tam	Well-differentiated thyroid carcinoma in Hong Kong Chinese patients under 21	J Am Coll Surg	2002	194(6)	711-6
Gemsenjager E, Heitz PU, Martina B, Schweizer	[Differentiated thyroid carcinoma. Surgery and significance of lymph node	Chirurg	2002	73(1)	38-43; discussion 43-4
Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich C, Dudczak R, Niederle	Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or	Clin Endocrinol (Oxf)	2002	56(3)	377-82
Chow SM, Law SC, Mendenhall WM, Au SK, Chan PT, Leung TW, Tong CC, Wong IS, Lau	Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy.	Int J Radiat Oncol Biol Phys	2002	52(3)	784-95
Gerard SK, Park	131I dosimetry and thyroid	J Nucl Med	2003	44(12)	2039-40; author reply
Kumar A, Bal	Differentiated thyroid cancer.	Indian J	2003	70(9)	707-13
Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, Zacher M, Spunt SL, Strickland DK,	Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature.	J Pediatr Surg	2003	38(11)	1574-80
Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M, Bartenstein	Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred	Thyroid	2003	13(10)	949-58

Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C,	Second primary malignancies in thyroid cancer patients.	Br J Cancer	2003	89(9)	1638–44
Reiners	Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat,	Eur J Nucl Med Mol Imaging	2003	30(7)	939–42
Besic N, Vidergar–Kralj B, Frkovic–Grazio S, Movrin–Stanovnik T,	The role of radioactive iodine in the treatment of Hurthle cell carcinoma of the thyroid.	Thyroid	2003	13(6)	577–84
Powers PA, Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Francis	Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in	J Pediatr Endocrinol Metab	2003	16(5)	693–702
Gotthardt M, Nowack M, Behe MP, Schipper ML, Schlieck A, Hoffken	Negative correlation between therapeutic success in radioiodine therapy and TcTUs: are TcTUs–adapted dose	Eur J Nucl Med Mol Imaging	2003	30(8)	1165–8
Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper	Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.	Nucl Med Commun	2003	24(5)	489–95
Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec	Dosimetry–guided radioactive iodine treatment in patients with metastatic differentiated	J Nucl Med	2003	44(3)	451–6
Kim TH, Yang DS, Jung KY, Kim CY, Choi	Value of external irradiation for locally advanced papillary thyroid cancer.	Int J Radiat Oncol Biol Phys	2003	55(4)	1006–12
Woodings	Radiation protection recommendations for I–131 thyrotoxicosis, thyroid cancer	Australas Phys Eng Sci Med	2004	27(3)	118–28
Mallick UK, Charalambous	Current issues in the management of differentiated	Nucl Med Commun	2004	25(9)	873–81
Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein	Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for	J Clin Endocrinol Metab	2004	89(8)	3668–76
Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, Purisch	Post I–131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution?	Clin Nucl Med	2004	29(12)	795–8
de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ,	Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid–stimulating hormone to treat metastatic differentiated	J Nucl Med	2004	45(9)	1549–54
Haq MS, McCready RV, Harmer	Treatment of advanced differentiated thyroid carcinoma	Nucl Med Commun	2004	25(8)	799–805
Hu YH, Wang PW, Wang ST, Lee CH, Chen HY, Chou FF, Huang YE, Huang	Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of	Nucl Med Commun	2004	25(8)	793–7

Stokkel MP, Verkooijen RB, Smit	Indium-111 octreotide scintigraphy for the detection of non-functioning metastases	Eur J Nucl Med Mol Imaging	2004	31(7)	950-7
Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Salle F,	Risk of second primary cancer following differentiated thyroid cancer.	Eur J Nucl Med Mol Imaging	2004	31(5)	685-91
Salvatori M, Perotti G, Rufini V, Maussier ML, Dottorini	Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma	Clin Endocrinol (Oxf)	2004	61(6)	704-10
Liu WS, Qi YF, Tang	[Poorly differentiated thyroid follicular carcinoma - a clinical	Ai Zheng	2004	23(9)	1081-4
Kita T, Yokoyama K, Higuchi T, Kinuya S, Taki J, Nakajima K, Michigishi T, Tonami	Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for	Ann Nucl Med	2004	18(4)	345-9
Causeret S, Lifante JC, Borson-Chazot F, Varcus F, Berger N, Peix	[Differentiated thyroid carcinoma in children and adolescents: therapeutic strategy according to clinic	Ann Chir	2004	129(6-7)	359-64
Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman	Management and outcome of recurrent well-differentiated thyroid carcinoma.	Arch Otolaryngol Head Neck	2004	130(7)	819-24
Lin JD, Chao TC, Hsueh	Follicular thyroid carcinomas with lung metastases: a 23-year	Endocr J	2004	51(2)	219-25
Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Mang O, Lau	Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine.	Pediatr Blood Cancer	2004	42(2)	176-83
Medvedec	Thyroid stunning in vivo and in	Nucl Med	2005	26(8)	731-5
Ma C, Xie J, Kuang	Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I	J Nucl Med	2005	46(7)	1164-70
Robbins RJ, Schlumberger	The evolving role of (131)I for the treatment of differentiated	J Nucl Med	2005	46 Suppl	28S-37S
Rubino C, Adjadj E, Doyon F, Shamsaldin A, Abbas TM, Caillou B, Colonna M, Cecarreli C, Schvartz C, Bardet S, Langlois C, Ricard M, Schlumberger M, de Vathaire	Radiation exposure and familial aggregation of cancers as risk factors for colorectal cancer after radioiodine treatment for thyroid carcinoma.	Int J Radiat Oncol Biol Phys	2005	62(4)	1084-9
Popova L, Hadjidekova V, Hadjieva T, Agova S,	Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for	Hell J Nucl Med	2005	8(1)	54-7
Violot D, M'Kacher R, Adjadj E, Dossou J, de Vathaire F,	Evidence of increased chromosomal abnormalities in French Polynesian thyroid	Eur J Nucl Med Mol Imaging	2005	32(2)	174-9
Pazaitou-Panayiotou K, Kaprara A, Boudina M, Georgiou E, Drimonitis A, Vainas I, Raptou E,	Thyroid carcinoma in children and adolescents: presentation, clinical course, and outcome of therapy in 23 children and adolescents in Northern	Hormones (Athens)	2005	4(4)	213-20

Iuchi Y, Sato K, Jimbo J, Inamura J, Shindo M, Ikuta K, Shinzaki H, Ohnishi K, Watanabe S,	[Acute lymphoblastic leukemia with t(4;11)(q21;q23) after iodine-131 treatment for thyroid cancer].	Rinsho Ketsueki	2005	46(11)	1202-7
Podnos YD, Smith D, Wagman LD,	Radioactive iodine offers survival improvement in	Surgery	2005	138(6)	1072-6; discussion 10
Rosa Pelizzo M, Toniato A, Boschin IM, Piotto A, Bernante P, Pagetta C, Palazzi M, Maria Guolo A, Preo P,	Locally advanced differentiated thyroid carcinoma: a 35-year mono-institutional experience in 280 patients.	Nucl Med Commun	2005	26(11)	965-8
Williams CE, Woodward	Management of the helpless patient after radioiodine	Nucl Med Commun	2005	26(10)	925-8
Alzahrani AS, Mohamed G, Al Shammary A, Aldasouqi S, Abdal Salam S, Shoukri	Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in	J Endocrinol Invest	2005	28(6)	540-6
Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger	Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor	J Clin Endocrinol Metab	2005	90(10)	5723-9
Heymann RS, Brent GA, Hershman	Anaplastic thyroid carcinoma with thyrotoxicosis and	Endocr Pract	2005	11(4)	281-4
Kozak OV, Sukach GG, Korchinskaya OI, Trembach AM, Turicina VL, Voit	Hierarchy of treatment variables affecting outcome of 131I therapy in thyroid cancer patients with lung metastases.	Exp Oncol	2005	27(2)	150-5
Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Reis JS, Purisch	Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer.	Ann Nucl Med	2005	19(3)	247-50
Worth AJ, Zuber RM, Hocking	Radioiodide (131I) therapy for the treatment of canine thyroid	Aust Vet J	2005	83(4)	208-14
Hod N, Hagag P, Baumer M, Sandbank J, Horne	Differentiated thyroid carcinoma in children and young adults: evaluation of	Clin Nucl Med	2005	30(6)	387-90
Abos Olivares MD, Pesquera Gonzalez	[Controversies in the follow-up and management of well-differentiated thyroid cancer.	Rev Esp Med Nucl	2005	24(3)	207-15
Yildirim	A model for predicting outcomes in patients with differentiated thyroid cancer	J Am Coll Surg	2005	200(3)	378-92
Panzegrau B, Gordon L, Goudy	Outpatient therapeutic 131I for thyroid cancer.	J Nucl Med Technol	2005	33(1)	28-30
Rosario PW, Barroso AL, Rezende LL, Padrao EL, Borges MA, Fagundes TA,	Ablative treatment of thyroid cancer with high doses of 131I without pre-therapy scanning.	Nucl Med Commun	2005	26(2)	129-32
Rasmuson T, Tavelin	Risk of parathyroid adenomas in patients with thyrotoxicosis	Acta Oncol	2006	45(8)	1059-61
Willegaignon J, Stabin MG, Guimaraes MI, Malvestiti LF, Sapienza MT, Maroni	Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer	Health Phys	2006	91(2)	123-7

Jentzen W, Schneider E, Freudenberg L, Eising EG, Gorges R, Muller SP, Brandau W, Bockisch	Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.	Nucl Med Commun	2006	27(8)	669–76
Sioka C, Kouraklis G, Zafirakis A, Manetou A, Dimakopoulos	Menstrual cycle disorders after therapy with iodine–131.	Fertil Steril	2006	86(3)	625–8
Chatal JF, Campion L, Kraeber–Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM,	Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti–carcinoembryonic–antigen radioimmunotherapy: a collaborative study with the	J Clin Oncol	2006	24(11)	1705–11
Kraeber–Bodere F, Rousseau C, Bodet–Milin C, Ferrer L, Faivre–Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM,	Targeting, toxicity, and efficacy of 2–step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I–labeled bivalent hapten in a phase I optimization clinical trial.	J Nucl Med	2006	47(2)	247–55
Yousuf K, Archibald	Brain metastases from papillary adenocarcinoma of the thyroid.	J Otolaryngol	2006	35(6)	366–72
Grigsby PW, Reddy RM, Moley JF, Hall	Contralateral papillary thyroid cancer at completion thyroidectomy has no impact	Surgery	2006	140(6)	1043–7; discussion 10
Chow SM, Yau S, Kwan CK, Poon PC, Law	Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and	Endocr Relat Cancer	2006	13(4)	1159–72
Cappelli C, Pirola I, Braga M, De Martino E, Morassi ML, Gandossi E, Mattanza C, Balzano R, Castellano M, Rosei	Prognostic factors in well–differentiated thyroid carcinoma in patients treated and followed in the same institution.	Ann Ital Chir	2006	77(2)	107–13
Verkooijen RB, Smit JW, Romijn JA, Stokkel	The incidence of second primary tumors in thyroid cancer patients is increased,	Eur J Endocrinol	2006	155(6)	801–6
Hay	Selective use of radioactive iodine in the postoperative management of patients with	J Surg Oncol	2006	94(8)	692–700
Robbins RJ, Driedger A, Magner	Recombinant human thyrotropin–assisted radioiodine therapy for patients with metastatic thyroid cancer who	Thyroid	2006	16(11)	1121–30
Brzozowska M, Roach	Timing and potential role of diagnostic I–123 scintigraphy in assessing radioiodine breast uptake before ablation in	Clin Nucl Med	2006	31(11)	683–7
Arias F, Vives R, Gomez–Dorronsoro	Cutaneous nodes in a patient with advanced papillary	Clin Transl Oncol	2006	8(9)	692–3
Bhattacharyya N, Chien	Risk of second primary malignancy after radioactive	Ann Otol Rhinol	2006	115(8)	607–10

Saghari M, Gholamrezanezhad A, Mirpour S, Eftekhari M, Takavar A, Fard-Esfahani A, Fallahi B, Beiki	Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.	Nucl Med Commun	2006	27(7)	567-72
Benbassat CA, Mechlis-Frish S, Hirsch	Clinicopathological characteristics and long-term outcome in patients with	World J Surg	2006	30(6)	1088-95
Lo CY, Chan WF, Lang BH, Lam KY,	Papillary microcarcinoma: is there any difference between	World J Surg	2006	30(5)	759-66
Segal K, Shpitzer T, Hazan A, Bachar G, Marshak G,	Invasive well-differentiated thyroid carcinoma: effect of treatment modalities on	Otolaryngol Head Neck Surg	2006	134(5)	819-22
Keum KC, Suh YG, Koom WS, Cho JH, Shim SJ, Lee CG, Park CS, Chung WY, Kim	The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea.	Int J Radiat Oncol Biol Phys	2006	65(2)	474-80
Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI,	Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers.	Cancer Lett	2006	238(1)	42-52
Walter MA, Turtschi CP, Schindler C, Minnig P, Muller-Brand J, Muller	The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort	J Nucl Med	2007	48(10)	1620-5
Freudenberg LS, Jentzen W, Marlowe RJ, Koska WW, Luster M, Bockisch	124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with	Exp Clin Endocrinol Diabetes	2007	115(10)	690-3
Sawka AM, Rotstein L, Brierley JD, Tsang RW, Thabane L, Gafni A, Straus S, Kamalanathan S, Zhao B, Goldstein DP, Rambaldini G,	Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States.	Thyroid	2007	17(12)	1235-42
Lin JD, Chao TC, Chen ST, Huang YY, Liou MJ, Hsueh	Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging.	Surg Oncol	2007	16(2)	107-13
Podnos YD, Smith DD, Wagman LD,	Survival in patients with papillary thyroid cancer is not	J Surg Oncol	2007	96(1)	3-7
Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller	Preoperative undetectable serum thyroglobulin in differentiated thyroid	Clin Endocrinol (Oxf)	2007	67(4)	547-51
Saint-Vil D, Emran MA, Lambert R, Alos N, Turpin S, Huot	Cumulative doses of adjunct 131I treatment depend on location of residual thyroid	J Pediatr Surg	2007	42(5)	853-6
Kucuk NO, Tari P, Tokmak E, Aras	Treatment for microcarcinoma of the thyroid--clinical	Clin Nucl Med	2007	32(4)	279-81
Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen	Increased cancer incidence after radioiodine treatment for hyperthyroidism.	Cancer	2007	109(10)	1972-9
Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi	Increased cardiovascular and cancer mortality after radioiodine treatment for	J Clin Endocrinol Metab	2007	92(6)	2190-6

Hindie E, Zanotti-Fregonara P, Duron F, Keller I, Bouchard P, Devaux	Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?	Clin Endocrinol (Oxf)	2007	66(3)	329-34
Reiners C, Demidchik YE, Drozd VM, Biko	Thyroid cancer in infants and adolescents after Chernobyl.	Minerva Endocrinol	2008	33(4)	381-95
Page C, Biet A, Zaatar R, Charlet L,	[Management of the papillary microcarcinoma of the thyroid	J Otolaryngol	2008	37(5)	649-56
Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap	Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for	Radiother Oncol	2008	89(1)	105-13
Lin JD, Lin KJ, Chao TC, Hseuh C, Tsang	Therapeutic outcomes of papillary thyroid carcinomas	Radiother Oncol	2008	89(1)	97-104
Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward	The risk of second primary malignancies up to three decades after the treatment of	J Clin Endocrinol Metab	2008	93(2)	504-15
Schlumberger MJ, Pacini	The low utility of pretherapy scans in thyroid cancer	Thyroid	2009	19(8)	815-6
Schneider AB, Viana MA, Ron	Weighing shadows: can meta-analysis help define the risk-benefit ratio of RAI treatment	Thyroid	2009	19(5)	435-6
Seaberg RM, Eski S, Freeman	Influence of previous radiation exposure on pathologic features and clinical outcome in patients	Arch Otolaryngol Head Neck	2009	135(4)	355-9
Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein	Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.	Thyroid	2009	19(5)	451-7
Riemann B, Schober	Therapeutic strategy of papillary microcarcinoma of the	Minerva Endocrinol	2009	34(1)	81-7
Biermann M, Pixberg M, Riemann B, Schuck A, Heinecke A, Schmid KW, Willich N, Dralle H, Schober	Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial.	Nuklearmedizin	2009	48(3)	89-98; quiz N15
Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini	Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between	Eur J Endocrinol	2009	160(3)	431-6
Duque-Fisher CS, Casiano R, Velez-Hoyos A, Londono-Bustamente	[Metastasis to the sinonasal region].	Acta Otorrinolaringol Esp	2009	60(6)	428-31
Maatouk J, Barklow TA, Zakaria W, Al-Abbadi	Anaplastic thyroid carcinoma arising in long-standing multinodular goiter following	Acta Cytol	2009	53(5)	581-3
Luster M, Handkiewicz-Junak D, Grossi A, Zacharin M, Taieb D, Cruz O, Hitzel A, Casas JA, Mader U, Dottorini	Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.	J Clin Endocrinol Metab	2009	94(10)	3948-53
Rios A, Manuel Rodriguez J, Balsalobre MD, Febrero B, Tebar J, Parrilla	[Distant metastases as the initial manifestation of follicular thyroid carcinoma].	Endocrinol Nutr	2009	56(4)	213-4

Chen PV, Osborne R, Ahn E, Avitia S, Juillard	Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated	Ear Nose Throat J	2009	88(7)	E01
Mihailovic JM, Stefanovic LJ, Malesevic MD, Erak MD, Tesanovic	Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial	Nucl Med Commun	2009	30(7)	558-64
Leenhardt	[Management of thyroid	J Radiol	2009	90(3 Pt :	354-61
Mazzaferri	A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental	J Clin Endocrinol Metab	2009	94(4)	1086-8
Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R, Fahey TJ 3	Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?	Thyroid	2009	19(5)	473-7
Gorgone S, Campenni A, Calbo E, Catalfamo A, Sciglitano P, Sofia L, Niceta M, Borzi R,	[Differentiated thyroid cancers].	G Chir	2009	30(1-2)	26-9
Naing S, Collins BJ, Schneider	Clinical behavior of radiation-induced thyroid cancer: factors	Thyroid	2009	19(5)	479-85
Miccoli P, Pinchera A, Materazzi G, Biagini A, Berti P, Faviana P, Molinaro E, Viola D, Elisei	Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy.	J Clin Endocrinol Metab	2009	94(5)	1618-22
Lazar L, Lebenthal Y, Steinmetz A, Yackobovitch-Gavan M, Phillip	Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal	J Pediatr	2009	154(5)	708-14
Terezakis SA, Lee KS, Ghossein RA, Rivera M, Tuttle RM, Wolden SL, Zelefsky MJ, Wong RJ, Patel SG, Pfister DG,	Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience.	Int J Radiat Oncol Biol Phys	2009	73(3)	795-801
Mendelsohn AH, Elashoff DA, Abemayor E, St John	Surgery for papillary thyroid carcinoma: is lobectomy enough?	Arch Otolaryngol Head Neck	2010	136(11)	1055-61
Sacks W, Fung CH, Chang JT, Waxman A, Braunstein	The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a	Thyroid	2010	20(11)	1235-45
Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah	Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases	Thyroid	2010	20(10)	1095-101
Panigrahi B, Roman SA, Sosa	Medullary thyroid cancer: are practice patterns in the United States discordant from	Ann Surg Oncol	2010	17(6)	1490-8

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman	Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.	Lancet Oncol	2010	11(10)	962-72
Abraham P, Acharya	Current and emerging treatment options for Graves'	Ther Clin Risk Manag	2010	6	29-40
Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga	Three distinctly different kinds of papillary thyroid microcarcinoma should be	World J Surg	2010	34(6)	1222-31
Listewnik MH, Birkenfeld B, Chosia M, Elbl B, Niedzialkowska K, Sawrymowicz	The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign thyroid diseases.	Endokrynol Pol	2010	61(5)	454-7
Reverter JL, Colome E, Halperin I, Julian T, Diaz G, Mora M, Sanmarti A, Puig-Domingo	[Comparative study of historical series of differentiated thyroid carcinoma in two tertiary hospitals in Spain versus North American series].	Endocrinol Nutr	2010	57(8)	364-9
Basbug M, Ozgun MT, Murat N, Batukan C, Ozcelik B, Kurtoglu	Prenatal diagnosis of fetal hypothyroidism after maternal radioactive iodine exposure	J Clin Ultrasound	2010	38(9)	506-8
Mulazimoglu M, Edis N, Tamam MO, Uyanik E, Ozpacaci	The evaluation of the external dose measurement of the patients treated with	Radiat Prot Dosimetry	2010	141(3)	233-8
Baranauskas Z, Valuckas KP, Tiskevicius	[Outcomes of long-term combined treatment in follicular thyroid carcinoma].	Medicina (Kaunas)	2010	46(4)	268-74
Kushchayev S, Kushchayeva Y, Theodore N, Preul MC, Clark	Percutaneous vertebroplasty for thyroid cancer metastases to the spine.	Thyroid	2010	20(5)	555-60
Silva F, Laguna R, Nieves-Rivera	Pediatric thyroid cancer with extensive disease in a Hispanic	J Pediatr Endocrinol	2010	23(1-2)	59-64
Baroli A, Pedrazzini L, Lomuscio G, Marzoli	Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from	Minerva Endocrinol	2010	35(1)	9-16
So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung	Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551	Surgery	2010	148(3)	526-31
Gerrard GE, O'Toole L, Roberts	Should we routinely offer a second admission for radioiodine to patients with	Clin Oncol (R Coll Radiol)	2010	22(2)	136-9
Bertagna F, Giubbini	To the editor: Long-term follow-up of patients with	World J Surg	2010	34(8)	1988-9; author reply 1
Malterling RR, Andersson RE, Falkmer S, Falkmer U, Nilehn E, Jarhult	Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.	Acta Oncol	2010	49(4)	454-9

Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C,	No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.	Eur J Nucl Med Mol Imaging	2010	37(2)	276-83
Grant CS, Stulak JM, Thompson GB, Richards ML, Reading CC, Hay	Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid	World J Surg	2010	34(6)	1239-46
Yipintsoi T, Premprabha T, Geater A, Thientunyakij T,	Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern	World J Surg	2010	34(2)	230-6
Asli IN, Baharfard N, Shafiei B, Tabei F, Javadi H, Seyedabadi M, Nabipour I, Assadi	Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131	Radiat Prot Dosimetry	2010	138(4)	376-81
Wang J, Yuan H, Ma Q, Liu X, Wang H, Jiang Y, Tian S, Yang	Interstitial 125I seeds implantation to treat spinal metastatic and primary	Med Oncol	2010	27(2)	319-26
Tuttle RM, Rondeau G, Lee	A risk-adapted approach to the use of radioactive iodine and external beam radiation in the	Cancer Control	2011	18(2)	89-95
Verburg FA, Luster M, Lassmann M, Reiners	(131)I therapy in patients with benign thyroid disease does not conclusively lead to a higher	Nuklearmedizin	2011	50(3)	93-9; quiz N20
Hurtado-Lopez LM, Melchor-Ruan J, Basurto-Kuba E, Montes de Oca-Duran ER, Pulido-Cejudo A, Athie-	Low-risk papillary thyroid cancer recurrence in patients treated with total thyroidectomy and adjuvant therapy vs. patients treated with partial thyroidectomy.	Cir Cir	2011	79(2)	118-25
Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, Haghpanah	Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine	Clin Nucl Med	2011	36(4)	277-82
Lubin	Radioactive iodine 1311 (RAI) treatment. The nearest to the "magic bullet" but should	Pediatr Endocrinol Rev	2011	9(1)	415-6
Papendieck P, Gruneiro-Papendieck L, Venara M, Acha O, Maglio S, Bergada I, Chiesa	Differentiated thyroid carcinoma: presentation and follow-up in children and adolescents.	J Pediatr Endocrinol Metab	2011	24(9-10)	743-8
Ozkan E, Soydal C, Araz M, Kucuk	Differentiated thyroid carcinomas in childhood:	J Pediatr Endocrinol	2011	24(9-10)	739-42
Nixon IJ, Ganly I, Patel S, Palmer FL, Whitcher MM, Tuttle RM, Shaha AR, Shah	The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-	Surgery	2011	150(6)	1242-9
Vaisman F, Tala H, Grewal R, Tuttle	In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly	Thyroid	2011	21(12)	1317-22

Soyluk O, Boztepe H, Aral F, Alagol F, Ozbey	Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term	Thyroid	2011	21(12)	1301–8
Kim EY, Kim TY, Kim WG, Yim JH, Han JM, Ryu JS, Hong SJ, Yoon JH, Gong G, Kim WB, Shong	Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated	Nucl Med Commun	2011	32(10)	954–9
Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini	Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better	Eur J Endocrinol	2011	165(3)	441–6
Huang BY, Lin JD, Chao TC, Lin KJ, Hseuh C, Tsang	Therapeutic outcomes of papillary thyroid cancer patients in different risk groups.	Oncology	2011	80(1–2)	123–9
Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly	Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who	Cancer	2011	117(19)	4439–46
van Dijk D, Plukker JT, van der Horst-Schrivers AN, Jansen L, Brouwers AH, Muller-Kobold A, Sluiter WJ, Links	The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial (1)(3)(1)I therapy.	Clin Endocrinol (Oxf)	2011	74(1)	104–10
Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, Doi	Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a	Endocr Relat Cancer	2012	19(5)	645–55
Haugen	Radioiodine remnant ablation: current indications and dosing	Endocr Pract	2012	18(4)	604–10
Zhao Y, Zhang Y, Liu XJ, Shi	Prognostic factors for differentiated thyroid carcinoma	Tumori	2012	98(2)	233–7
Bal C, Chandra P, Kumar A, Dwivedi	A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant	Nucl Med Commun	2012	33(10)	1039–47
Daumerie C, Boschi A, Perros	Is Recombinant Human TSH a Trigger for Graves'	Eur Thyroid J	2012	1(2)	105–9
Mallick U, Harmer C, Hackshaw A, Moss	Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer	Clin Oncol (R Coll Radiol)	2012	24(3)	159–61
Adedapo KS, Fadiji IO, Orunmuyi AT, Ejeh JE, Osifo	High default rate in thyroid cancer management in Ibadan, Nigeria: a need for health	Afr J Med Med Sci	2012	41 Suppl	105–9
Brownlie BJ, Turner J, Abdelaal	Deaths due to differentiated thyroid cancer: a South Island,	N Z Med J	2012	125(136	13–21
Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly	Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need	Surgery	2012	152(6)	1096–105
Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle	Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer	Thyroid	2012	22(10)	1007–15
Lim I, Kim SK, Hwang SS, Kim SW, Chung KW, Kang HS, Lee	Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early	Ann Nucl Med	2012	26(10)	777–86

Rosenbaum-Krumme SJ, Gorges R, Bockisch A, Binse	(1)(8)F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine	Eur J Nucl Med Mol Imaging	2012	39(9)	1373-80
Kutluhan A, Yalciner G, Bozdemir K, Ozdemir E, Tarlak B, Bilgen	Papillary thyroid carcinoma with metastasis to the temporooccipital skull: a case report.	Kulak Burun Bogaz Ihtis Derg	2012	22(3)	160-3
Ozpacaci T, Mulazimoglu M, Tamam MO, Leblebici C, Yildiz K, Uyanik E,	Intraocular and orbital metastasis as a rare form of clinical presentation of insular thyroid cancer.	Ann Endocrinol (Paris)	2012	73(3)	222-4
Hartl DM, Leboulleux S, Al Ghuzlan A, Baudin E, Chami L, Schlumberger M, Travagli	Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma.	Ann Surg	2012	255(4)	777-83
Kim K, Kim SJ, Kim IJ, Kim YK, Kim BS, Pak	Clinical significance of diffuse hepatic visualization and thyroid bed uptake on post-ablative	Onkologie	2012	35(3)	82-6
Enomoto Y, Enomoto K, Uchino S, Shibuya H, Watanabe S, Noguchi	Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation	World J Surg	2012	36(6)	1241-6
Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DS, Daniels	Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after	Thyroid	2012	22(4)	369-76
Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffe S, Pochart JM, Cochet I, Crevisy E, Dalac A, Papathanassiou D, Toubeau	Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.	J Clin Endocrinol Metab	2012	97(5)	1526-35
Lang BH, Wong IO, Wong KP, Cowling BJ, Wan	Risk of second primary malignancy in differentiated thyroid carcinoma treated with	Surgery	2012	151(6)	844-50
Qin C, Cau W, Zhang Y, Mghanga FP, Lan X, Gao Z, An	Correlation of clinicopathological features and expression of molecular	Clin Nucl Med	2012	37(3)	e40-6
Vrachimis A, Schober O, Riemann	Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and	Nuklearmedizin	2012	51(3)	67-72
Huang CH, Chao TC, Hseuh C, Lin KJ, Ho TY, Lin SF, Lin	Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid	Pediatr Surg Int	2012	28(5)	489-94
de Meer SG, Dauwan M, de Keizer B, Valk GD, Borel Rinkes IH, Vriens	Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients	World J Surg	2012	36(6)	1262-7
Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi	Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes,	World J Surg	2012	36(6)	1274-8
Wu G, Fraser S, Pai SI, Farrag TY, Ladenson PW, Tufano	Determining the extent of lateral neck dissection necessary to establish regional disease control and avoid	Head Neck	2012	34(10)	1418-21

Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo	Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-	Clin Oncol (R Coll Radiol)	2012	24(3)	162-8
Sun XS, Guevara N, Fakhry N, Sun SR, Marcy PY, Santini J, Bosset JF, Thariat	[Radiation therapy in thyroid cancer].	Cancer Radiother	2013	17(3)	233-43; quiz 255-6, 25
Lang BH, Ng SH, Lau LL, Cowling BJ, Wong KP, Wan	A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in	Thyroid	2013	23(9)	1087-98
Azizmohammadi Z, Tabei F, Shafiei B, Babaei AA, Jukandan SM, Naghshine R, Javadi H, Nabipour I, Assadi M, Asli	A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment.	Hell J Nucl Med	2013	16(2)	103-6
An YS, Yoon JK, Lee SJ, Song HS, Yoon SH, Jo	Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer.	Ann Nucl Med	2013	27(4)	386-91
Kim HJ, Kim NK, Choi JH, Kim SW, Jin SM, Suh S, Bae JC, Min YK, Chung JH, Kim	Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.	Clin Endocrinol (Oxf)	2013	78(4)	614-20
Kruijff S, Aniss AM, Chen P, Sidhu SB, Delbridge LW, Robinson B, Clifton-Bligh RJ, Roach P, Gill AJ, Learoyd D,	Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.	Surgery	2013	154(6)	1337-44; discussion 13
Liu WS, Zhang GF, Xu	[Management and prognostic factors for 119 patients with	Zhonghua Zhong Liu	2013	35(10)	778-82
Wienhold R, Scholz M, Adler JR, G Nster C, Paschke	The management of thyroid nodules: a retrospective analysis of health insurance	Dtsch Arztebl Int	2013	110(49)	827-34
Young S, Harari A, Smooke-Praw S, Ituarte PH, Yeh	Effect of reoperation on outcomes in papillary thyroid cancer.	Surgery	2013	154(6)	1354-61; discussion 13
Pedrazzini L, Baroli A, Marzoli L, Guglielmi R, Papini	Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231	Minerva Endocrinol	2013	38(3)	269-79
Vrachimis A, Riemann B, Gerss J, Maier T, Schober	Peace of mind for patients with differentiated thyroid cancer?	Nuklearmedizin	2013	52(4)	115-20
Saengsuda	Radioiodine remnant ablation in low-risk differentiated thyroid	J Med Assoc Thai	2013	96(5)	614-24
Park S, Jeong JS, Ryu HR, Lee CR, Park JH, Kang SW, Jeong JJ, Nam KH, Chung WY, Park	Differentiated thyroid carcinoma of children and adolescents: 27-year experience in the yonsei university health system.	J Korean Med Sci	2013	28(5)	693-9

Reiners C, Biko J, Haenscheid H, Hebestreit H, Kirinjuk S, Baranowski O, Marlowe RJ, Demidchik E, Drozd V, Demidchik	Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.	J Clin Endocrinol Metab	2013	98(7)	3039-48
Kuo EJ, Goffredo P, Sosa JA, Roman	Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal	Thyroid	2013	23(10)	1305-11
Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, Belardini V, Brianzoni E, Pacini	Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.	Eur J Endocrinol	2013	169(1)	23-9
Meixner M, Hellmich M, Dietlein M, Kobe C, Schicha H, Schmidt	Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th	Nuklearmedizin	2013	52(3)	71-80
Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge	Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic	Thyroid	2013	23(9)	1099-105
Hod R, Bachar G, Sternov Y, Shvero	Insular thyroid carcinoma: a retrospective clinicopathologic	Am J Otolaryngol	2013	34(4)	292-5
Ito Y, Hirokawa M, Masuoka H, Yabuta T, Kihara M, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Ibrahimpasic T,	Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis.	Endocr J	2013	60(5)	637-42
Ghossein R, Carlson DL, Chernichenko N, Nixon I, Palmer FL, Lee NY, Shaha AR, Patel SG, Tuttle RM, Balm AJ, Shah JP, Ganly	Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan-Kettering Cancer Center experience.	Thyroid	2013	23(8)	997-1002
Amdur RJ, Dan T, Mazzaferri	Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating	Am J Clin Oncol	2013	36(4)	348-53
Hilly O, Stern-Shavit S, Iran S, Feinmesser	Treatment decisions and adherence to guidelines in the treatment of low risk papillary	Isr Med Assoc J	2014	16(9)	548-52
Rokni H, Sadeghi R, Moossavi Z, Treglia G, Zakavi	Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular	Int J Endocrinol Metab	2014	12(2)	e14424
Wang TS, Goffredo P, Sosa JA, Roman	Papillary thyroid microcarcinoma: an over-	World J Surg	2014	38(9)	2297-303
Iacobone M, Jansson S, Barczynski M, Goretzki	Multifocal papillary thyroid carcinoma--a consensus report of the European Society of	Langenbecks Arch Surg	2014	399(2)	141-54
Karyampudi A, Hamide A, Halanaik D, Sahoo JP,	Radioiodine therapy in patients with Graves' disease and the effects of prior carbimazole	Indian J Endocrinol Metab	2014	18(5)	688-93

Verburg FA, Mader U, Reiners C, Hanscheid	Long-term survival in differentiated thyroid cancer is worse after low-activity initial	J Clin Endocrinol Metab	2014	99(12)	4487-96
Guy A, Hirsch D, Shohat T, Bachar G, Tirosh A, Robenshtok E, Shimon I, Benbassat	Papillary thyroid cancer: factors involved in restaging N1 disease after total thyroidectomy and radioactive iodine treatment.	J Clin Endocrinol Metab	2014	99(11)	4167-73
Liu B, Peng W, Huang R, Tian R, Zeng Y, Kuang	Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic	Radiology	2014	273(1)	211-9
Ito Y, Miyauchi A, Ito M, Yabuta T, Masuoka H, Higashiyama T, Fukushima M, Kobayashi K, Kihara	Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy.	Endocr J	2014	61(8)	821-4
Lupoli R, Cacciapuoti M, Tortora A, Barba L, Verde N, Romano F, Vastarella M, Fonderico F, Masone S, Milone M, Lupoli G, Lupoli	Clinical outcome in differentiated thyroid carcinoma and microcarcinoma.	Int J Surg	2014	12 Suppl	S148-51
Tresoldi AS, Sburlati LF, Rodari M, Schinkelshoek M, Perrino M, De Leo S, Montefusco L, Colombo P, Arosio M, Lania AG, Fugazzola L, Chiti	Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.	J Endocrinol Invest	2014	37(8)	709-14
Astl J, Chovanec M, Lukes P, Katra R, Dvorakova M, Vlcek P, Sykorova P, Betka	Thyroid carcinoma surgery in children and adolescents - 15 years experience surgery of pediatric thyroid carcinoma.	Int J Pediatr Otorhinolaryngol	2014	78(7)	990-4
Hasbek Z, Turgut B, Kilicli F, Altuntas EE, Yucel	Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation	Asian Pac J Cancer Prev	2014	15(6)	2523-7
Ardito G, Avenia N, Giustozzi E, Salvatori M, Fadda G, Ardito F, Revelli	Papillary thyroid microcarcinoma: proposal of treatment based on histological prognostic factors evaluation.	Ann Ital Chir	2014	85(1)	1-5
De Crea C, Raffaelli M, Sessa L, Ronti S, Fadda G, Bellantone C, Lombardi	Actual incidence and clinical behaviour of follicular thyroid carcinoma: an institutional experience.	ScientificWorldJournal	2014	2014	952095
Lee J, Song Y, Soh	Central lymph node metastasis is an important prognostic factor in patients with papillary	J Korean Med Sci	2014	29(1)	48-52
Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, Hong SJ, Shong YK, Kim	Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small	Thyroid	2014	24(5)	820-5
Goldfarb M, Sener	Comparison of radioiodine utilization in adolescent and	Endocr Pract	2014	20(5)	405-11
Rosario PW, Calsolari	Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma	Thyroid	2014	24(5)	826-31

Kotb MH, Zaher AM, Abd El-Wahab MA, Abulkheir IL, Hussein M, Salem	Prognostic value of p27 in follicular thyroid carcinoma and its relation to radioactive iodine response: does it aid in the	Appl Immunohistochem Mol Morphol	2014	22(7)	511-7
Kim SK, Yun GY, Kim KH, Park SK, Choi HY, Ha SK, Park	Severe hyponatremia following radioactive iodine therapy in patients with differentiated	Thyroid	2014	24(4)	773-7
Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, Chung KW, Ryu JS, Hong SJ, Shong YK,	Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid	Eur J Endocrinol	2014	170(1)	23-30
Zoghlami A, Roussel F, Sabourin JC, Kuhn JM, Marie JP, Dehesdin D, Choussy	BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.	Eur Ann Otorhinolaryngol Head Neck Dis	2014	131(1)	7-13
Akkas BE, Demirel BB, Vural	Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated	Thyroid	2014	24(2)	287-95
Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly	The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of	Eur Thyroid J	2015	4(3)	149-63
Xu G, Wu T, Ge L, Li	A Systematic Review of Adjuvant Interventions for	Oncol Res Treat	2015	38(7-8)	368-72
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa	Adjuvant radioactive iodine therapy is associated with improved survival for patients	J Clin Endocrinol Metab	2015	100(4)	1529-36
Sacks W, Wong RM, Bresee C, Braunstein	Use of evidence-based guidelines reduces radioactive iodine treatment in patients	Thyroid	2015	25(4)	377-85
Fu H, Ma C, Tang L, Wu F, Liu B, Wang	Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine	Q J Nucl Med Mol Imaging	2015	59(1)	121-8
Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M,	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.	Endocr Relat Cancer	2015	22(6)	877-87
Sawka AM, Straus S, Rodin G, Thorpe KE, Ezzat S, Gafni A, Goldstein	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-	Trials	2015	16	302
Jacob JJ, Stephen C, Paul TV, Thomas N, Oommen R, Seshadri	No impact of dietary iodine restriction in short term development of hypothyroidism	Indian J Endocrinol Metab	2015	19(1)	60-5
Czepczynski R, Matysiak-Grzes M, Gryczynska M, Baczyk M, Wyszomirska A,	Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity.	Arch Immunol Ther Exp (Warsz)	2015	63(2)	147-54
Shen J, Wang S, Zhao X, Shao X, Jiang X, Dai Y, Xu S,	Skull metastasis from follicular thyroid carcinoma: report of three cases and review of	Int J Clin Exp Pathol	2015	8(11)	15285-93

Kang	Using ultrasound radio frequency technology to assess regression of the structure and function of the carotid artery	Arch Med Sci	2015	11(6)	1236-43
Kao YH, Gan HK, Zaheer S, Lam WW, Loke KS, Wong WY, Ng DC, Goh	Gender, Race, and Age at Diagnosis as Risk Factors for Metastasis or Recurrence among 1,657 Thyroid Cancer	Oncol Res Treat	2015	38(12)	679-82
Al-Qahtani KH, Al Asiri M, Tunio MA, Aljohani NJ, Bayoumi Y, Fatani H, AlHadab	Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience	J Otolaryngol Head Neck Surg	2015	44	51
Zaman MU, Fatima N, Zaman U, Sajjad Z, Zaman A, Tahseen	Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome	Indian J Nucl Med	2015	30(4)	309-13
Yang SP, Bach AM, Tuttle RM, Fish	SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN	Endocr Pract	2015	21(12)	1372-9
Ryodi E, Metso S, Jaatinen P, Huhtala H, Saaristo R, Valimaki M, Auvinen	Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism.	J Clin Endocrinol Metab	2015	100(10)	3710-7
Liu FH, Kuo SF, Hsueh C, Chao TC, Lin	Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.	J Surg Oncol	2015	112(2)	149-54
Ahn HY, Min HS, Yeo Y, Ma SH, Hwang Y, An JH, Choi HS, Keam B, Im SA, Park DJ, Park IA, Noh DY, Youn YK, Chung JK, Cho BY, Park SK,	Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.	J Clin Endocrinol Metab	2015	100(9)	3486-93
Seo GH, Cho YY, Chung JH, Kim	Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with	Thyroid	2015	25(8)	927-34
Marti JL, Jain KS, Morris	Increased risk of second primary malignancy in pediatric and young adult patients	Thyroid	2015	25(6)	681-7
Orlov S, Salari F, Kashat L, Freeman JL, Vescan A, Witterick IJ, Walfish	Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification	Endocrine	2015	50(1)	130-7
Gamper EM, Wintner LM, Rodrigues M, Buxbaum S, Nilica B, Singer S, Giesinger JM, Holzner B, Virgolini	Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme.	Eur J Nucl Med Mol Imaging	2015	42(8)	1179-88
Semrad TJ, Semrad AM, Farwell DG, Chen Y, Cress	Initial treatment patterns in younger adult patients with differentiated thyroid cancer in	Thyroid	2015	25(5)	509-13
Avram AM, Esfandiari NH, Wong	Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification	J Clin Endocrinol Metab	2015	100(5)	1895-902
Lorenz R, Buck A, Reiners	[In-patient nuclear medicine therapy in Germany from 2010	Nuklearmedizin	2015	54(2)	61-8

Kiernan CM, Parikh AA, Parks LL, Solorzano	Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer:	J Am Coll Surg	2015	220(4)	617–25
Wang LY, Palmer FL, Nixon IJ, Tuttle RM, Shah JP, Patel SG, Shaha AR, Ganly	Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary	Ann Surg Oncol	2015	22(11)	3530–6
Maier TM, Schober O, Gerss J, Gorlich D, Wenning C, Schaefers M, Riemann B,	Differentiated thyroid cancer patients more than 60 years old paradoxically show an increased life expectancy.	J Nucl Med	2015	56(2)	190–5
Shivaprasad C, Prasanna Kumar	Long-term carbimazole pretreatment reduces the	Indian J Endocrinol	2015	19(1)	84–8
Qiu ZL, Shen CT, Luo	Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated	Thyroid	2015	25(2)	229–37
Garg A, Chopra S, Ballal S, Soundararajan R, Bal	Differentiated thyroid cancer in patients over 60 years of age at presentation: a retrospective	J Geriatr Oncol	2015	6(1)	29–37
Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, Kang KW, Yi KH, Park DJ, Lee DS, Chung JK, Cho BY, Park	The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.	Clin Endocrinol (Oxf)	2015	83(1)	117–23
Kim KJ, Kim SM, Lee YS, Chung WY, Chang HS, Park	Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor	Ann Surg Oncol	2015	22(1)	125–31
Su DH, Chang SH, Chang	The impact of locoregional recurrences and distant metastases on the survival of	Clin Endocrinol (Oxf)	2015	82(2)	286–94
Scott E, Learoyd D, Clifton-Bligh	Therapeutic options in papillary thyroid carcinoma: current	Future Oncol	2016	12(22)	2603–2613
Dietlein M, Drzezga	[Ablative Radioiodtherapie bei niedrigem und intermediarem Rezidivrisiko. Hohere	Nuklearmedizin	2016	55(3)	71–6
Wang J, Qin	Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of	Br J Radiol	2016		20160418
Chen P, Feng HJ, Ouyang W, Wu JQ, Wang J, Sun YG, Xian JL, Huang	RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM	Endocr Pract	2016	22(9)	1048–56
Zhang Y, Liang J, Li H, Cong H, Lin	Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a	Nucl Med Commun	2016	37(2)	110–5
Li JH, He ZH, Bansal V, Hennessey	Low iodine diet in differentiated thyroid cancer: a review.	Clin Endocrinol	2016	84(1)	3–12
de la Fouchardiere	[Lenvatinib in radioiodine refractory thyroid carcinomas].	Bull Cancer	2016	103(11)	905–910

Klein Hesselink EN, Brouwers AH, de Jong JR, van der Horst-Schrivers AN, Coppes RP, Lefrandt JD, Jager PL, Vissink	Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.	J Nucl Med	2016	57(11)	1685-1691
Gao X, Zhang X, Zhang Y, Hua W, Maimaiti Y, Gao	Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study	Medicine (Baltimore)	2016	95(40)	e5067
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman	Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer	Lancet Oncol	2016	17(9)	1272-82
Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl	Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict	Thyroid	2016	26(8)	1004-9
la Cour JL, Andersen UB, Sorensen CH, Nygaard B, Jensen	Radioiodine Therapy Does Not Change the Atherosclerotic Burden of the Carotid Arteries.	Thyroid	2016	26(7)	965-71
Canto AU, Dominguez PN, Jimeno CA, Obaldo	Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment	Endocrinol Metab (Seoul)	2016	31(1)	168-73
Louvet C, De Bellis A, Pereira B, Bournaud C, Kelly A, Maqdasy S, Roche B, Desbiez F, Borson-Chazot F, Tauveron I, Batisse-Lignier	Time course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer.	Medicine (Baltimore)	2016	95(48)	e5474
Hollingsworth B, Senter L, Zhang X, Brock GN, Jarjour W, Nagy R, Brock P, Coombes KR, Kloos RT, Ringel MD, Sipos J, Lattimer I, Carrau R, Jhiang	Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.	J Clin Endocrinol Metab	2016	101(11)	4085-4093
Deutschmann MW, Chin-Lenn L, Nakoneshny SC, Dort JC, Pasieka JL, Chandarana	Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.	J Otolaryngol Head Neck Surg	2016	45(1)	55
Mohan V, Lind	A review of treatment options for Graves' disease: why total thyroidectomy is a viable option	J Community Hosp Intern	2016	6(4)	32369
Matthews TJ, Chua E, Gargya A, Clark J, Gao K, Elliott	Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in	J Laryngol Otol	2016	130 Suppl	S50-3
Banerjee M, Wiebel JL, Guo C, Gay B, Haymart	Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective	BMJ	2016	354	i3839

Cramon P, Winther KH, Watt T, Bonnema SJ, Bjorner JB, Ekholm O, Groenvold M, Hegedus L, Feldt-Rasmussen U, Rasmussen	Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.	Thyroid	2016	26(8)	1010-8
Rosario PW, Mourao GF, Calsolari	Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and	Nucl Med Commun	2016	37(11)	1148-53
Winter J, Winter M, Krohn T, Heinzel A, Behrendt FF, Tuttle RM, Mottaghy FM, Verburg	Patients with high-risk differentiated thyroid cancer have a lower I-131 ablation success rate than low-risk ones in spite of a high ablation	Clin Endocrinol (Oxf)	2016	85(6)	926-931
Klein Hesselink MS, Nies M, Bocca G, Brouwers AH, Burgerhof JG, van Dam EW, Havekes B, van den Heuvel-Eibrink MM, Corssmit EP, Kremer LC, Netea-Maier RT, van der Pal HJ, Peeters RP, Schmid KW, Smit JW, Williams GR, Plukker JT, Ronckers CM, van Santen HM, Tissing WJ, Links	Pediatric Differentiated Thyroid Carcinoma in The Netherlands: A Nationwide Follow-Up Study.	J Clin Endocrinol Metab	2016	101(5)	2031-9
Lin CM, Yeh PT, Doyle P, Tsan YT, Chen	Association Between 131I Treatment for Thyroid Cancer and Risk of Receiving Cataract	J Nucl Med	2016	57(6)	836-41
Ruhlmann M, Binse I, Bockisch A, Rosenbaum-Krumme	Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.	Nuklearmedizin	2016	55(3)	99-103
Heaton CM, Chang JL, Orloff	Prognostic Implications of Lymph Node Yield in Central and Lateral Neck Dissections	Thyroid	2016	26(3)	434-40
Rosario PW, Mourao GF, Calsolari	Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in	Clin Endocrinol (Oxf)	2016	85(3)	453-8
Prpic M, Kruljac I, Kust D, Kirigin LS, Jukic T, Dabelic N, Bolanca A, Kusic	Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated	Endocrine	2016	52(3)	602-8
Lin CY, Lin CL, Huang WS, Kao	Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving	J Nucl Med	2016	57(5)	685-90
Pathak KA, Klonisch TC, Nason	Stage II differentiated thyroid cancer: A mixed bag.	J Surg Oncol	2016	113(1)	94-7
So K, Smith RE, Davis	Radiotherapy in well-differentiated thyroid cancer: is	ANZ J Surg	2016	86(9)	696-700
Lee DY, Won JK, Lee SH, Park DJ, Jung KC, Sung MW, Wu HG, Kim KH, Park YJ,	Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid	Thyroid	2016	26(3)	404-13

Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ, Liu	Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based	J Natl Cancer Inst	2016	108(2)	
Hakala TT, Sand JA, Jukkola A, Huhtala HS, Metso S, Kellokumpu-Lehtinen	Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.	Int J Clin Oncol	2016	21(2)	231-239
Souza MC, Momesso DP, Vaisman F, Vieira Neto L, Martins RA, Corbo R, Vaisman	Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary	Arch Endocrinol Metab	2016	60(1)	9-15
Scerrino G, Attard A, Melfa GI, Raspanti C, DI Giovanni S, Attard M, Inviati A, Mazzola S, Modica G, Gulotta G, Bonventre	Role of prophylactic central neck dissection in cN0-papillary thyroid carcinoma: results from a high-prevalence area.	Minerva Chir	2016	71(3)	159-67
Ballal S, Soundararajan R, Garg A, Chopra S,	Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not	Clin Endocrinol (Oxf)	2016	84(3)	408-16
Jeon YW, Ahn YE, Chung WS, Choi HJ, Suh	Radioactive iodine treatment for node negative papillary thyroid cancer with capsular	Asia Pac J Clin Oncol	2016	12(1)	e167-73
Qin Y, Yao L, Shao F, Yang K, Tian	Methodological Quality Assessment of Meta-Analyses	Horm Metab Res	2017		
Parker WA, Edafe O, Balasubramanian	Long-term treatment-related morbidity in differentiated	Pragmat Obs Res	2017	8	57-67
Yuan J, Lu X, Yue	Comparison of curative effect of 131I and antithyroid drugs in	Minerva Endocrinol	2017		
Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, Suh I, C L, Duh	Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable	Surgery	2017	161(1)	127-133
Brose MS, Worden FP, Newbold KL, Guo M, Hurria	Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory	J Clin Oncol	2017	35(23)	2692-2699
Qu Y, Huang R, Li	Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid	Ann Nucl Med	2017	31(1)	71-83
Giesecke P, Frykman V, Wallin G, Lonn S, Discacciati A, Torring O, Rosenqvist	All-cause and cardiovascular mortality risk after surgery versus radioiodine treatment for hyperthyroidism.	Br J Surg	2017		
Yang D, Xue J, Ma W, Liu F, Fan Y, Rong J, Yang A, Yu	Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine	Nucl Med Commun	2017		
Alonso GT, Rabon S, White	Weight gain after treatment of Graves' disease in children.	Clin Endocrinol	2017		
Viola D, Giani C, Mazzeo S, Ugolini C, Ciampi R, Molinaro E, Agate L, Borrelli N, Chella A, Fontanini G, Basolo F, Elisei	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.	J Clin Endocrinol Metab	2017	102(9)	3091-3096

Vagney M, Desquilbet L, Reyes-Gomez E, Delisle F, Devauchelle P, Rodriguez-Pineiro MI, Rosenberg D, de	Survival times for cats with hyperthyroidism treated with a 3.35 mCi iodine-131 dose: a retrospective study of 96 cases.	J Feline Med Surg	2017		1098612X17718416
Al Eyadeh AA, Al-Sarihin KM, Etewi SM, Al-Omari AA, Al-Asa'd RA, Haddad	Thyroid cancer post radioactive iodine treatment for hyperthyroidism (case series and review of the literature).	Endokrynol Pol	2017		
Giesecke P, Rosenqvist M, Frykman V, Friberg L, Wallin G, Hoijer J, Lonn S, Torring	Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic	Thyroid	2017	27(7)	878-885
Zhang H, Cai Y, Zheng L, Zhang Z, Jiang	Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated	Hell J Nucl Med	2017	20(1)	3-10
Scerrino G, Melfa G, Raspanti C, Attard A, Mazzola S, Gullo R, Bonventre S, Attard M, Cocorullo G, Gulotta	The prevalence of post-thyroidectomy chronic asthenia: a prospective cohort study.	Langenbecks Arch Surg	2017	402(7)	1095-1102
Cebulska-Wasilewska A, Krzysiek M, Krajewska G, Stepien A, Krajewski	Retrospective Biological Dosimetry at Low and High Doses of Radiation and Radioiodine Impact on Individual	Genome Integr	2017	8	2
Al-Qurayshi Z, Shama MA, Randolph GW, Kandil	Minimal extrathyroidal extension does not affect survival of well-differentiated	Endocr Relat Cancer	2017	24(5)	221-226
Lucy JM, Peterson ME, Randolph JF, Scrivani PV, Rishniw M, Davignon DL, Thompson MS, Scarlett	Efficacy of Low-dose (2 millicurie) versus Standard-dose (4 millicurie) Radioiodine Treatment for Cats with Mild-to-Moderate Hyperthyroidism.	J Vet Intern Med	2017	31(2)	326-334
Kim J, Cho SG, Kang SR, Kwon SY, Cho DH, Cho JS, Song	Preparation for radioactive iodine therapy is not a risk factor for the development of	Medicine (Baltimore)	2017	96(5)	e6004
Jeong JH, Kong EJ, Jeong SY, Lee SW, Cho IH, Ah Chun K, Lee J, Ahn	Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk	Nucl Med Commun	2017	38(3)	228-233
Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle	Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.	J Nucl Med	2017	58(5)	717-722
Parameswaran R, Shulin Hu J, Min En N, Tan WB, Yuan	Patterns of metastasis in follicular thyroid carcinoma and the difference between early	Ann R Coll Surg Engl	2017	99(2)	151-154
Sabet A, Binse I, Dogan S, Koch A, Rosenbaum-Krumme SJ, Biersack HJ, Biermann K, Ezziddin	Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid	Eur J Nucl Med Mol Imaging	2017	44(2)	190-195

5

2040

76-7

58

344-5

361-2